Internal Medicine/Hematology/Oncology

 

Haifaa Abdulhaq, MD

Assistant Clinical Professor, UCSF

 

  Medical School: Damascus University, Syria
  Residency: Damascus University Hospitals, Syria
Western Pennsylvania Hospital, Pittsburgh, PA
  Fellowship Rheumatology, Damascus University Hospitals, Syria
Hematology/Oncology, Western Pennsylvania Hospitals, Pittsburgh, PA
  Board Certified: Internal Medicine, Hematology, Oncology
  Awards and Recognition:
  1. National achievement award
  2. Ranked 2nd among  Syrian high school graduates (50,000 students)
  3. Al Basel Prize
  4. Ranked 1st among Damascus University School of medicine graduates (> 700 students)
  5. Best junior house staff award
  6. Best senior house staff award
 
  Publications:
  1. Abdulhaq H,  Rossetti JM, Shadduck RK,. The myelodysplastic syndromes. Oncology Special Edition. 2006; 9(6): 97-101

  2. Lister J, Abdulhaq H. The role of Proteasome Inhibition in Cancer Therapy. The American Journal of Oncology Review. 2006; 5 (6), supp (6): 15-16.

  3. Abdulhaq H,  Rossetti JM, Shadduck RK.   The myelodysplastic syndromes. Clinical Oncology News. 4/ 2006.

  4. Shadduck RK, Latsko JM,  Rossetti JM, Haq B, Abdulhaq H. Recent advances in myelodysplastic syndromes. Experimental Hematology. 2007; 35 (4): 137-143

  5. Abdulhaq H,  Rossetti, JM.  The role of azacitidine in treatment of myelodysplastic syndromes. Expert opinion on investigational drugs. 2007; 16 (12): 1967-1975

  6. Abdulhaq H,  Rossetti JM, Shadduck RK,. Myelodysplasia: Recent advances: Oncology Special Edition. 2007; 10: 145-152

  7. Talreja N, Abdulhaq H, Shadduck RK, et al. Erythroid variant of chronic myeloid leukemia, letter to the editor. Leukemia. 2008; 22 (4): 867-870

  8. Abdulhaq H,  C Geyer. Safety of adjuvant endocrine therapy in postmenopausal women with breast cancer. Accepted for publication in the American Journal of Clinical Oncology.

 

Research:

     

    Abdulhaq H,
    Stefanovic A,  Sudan N,  Rossetti JM
      Response to therapy with azacitidine (AZA) in patients with myelodysplastic syndromes.   2002
    Kaplan R, Abduhaq H, Kennedy M   Phase I/II Study of the Use of Rituximab in Patients with Antiphospholipid Syndrome (APLS)   2005- present
    Haq B, Abdulhaq H,  Rossetti JM,  Lynch E,  Lister J   Ki 67 and Activated Caspase 3 as outcome predictors in patients with mantle cell lymphoma (MCL)   2007- present
    Abdulhaq H, Haq B,  Rossetti JM,  Shadduck RK,  Lister J, et al.   Response to azacitidine in myelomonocytic leukemia   2008